into fine mist for inhalation over longer periods.

Common Nasal Dosage Forms:

• Nasal Sprays: Solutions or suspensions delivered as droplets onto the nasal mucosa.
• Nasal Powders: Dry formulations designed for improved stability and mucosal retention.
• Nasal Gels: Semi-solid systems offering prolonged contact time and minimal dripping.

Both routes offer fast absorption due to the high vascularity of the lung and nasal mucosa. While inhalation forms are commonly used for asthma, COPD, and cystic fibrosis, nasal products are increasingly used for vaccines, peptides, and CNS-active drugs.

Common Challenges in Inhalation and Nasal Dosage Forms

Designing effective respiratory and nasal formulations involves complex interplay between formulation properties, device functionality, and patient physiology.

1. Particle Size and Aerosolization

For pulmonary delivery, particle size must be optimized between 1–5 µm for deep lung deposition. Larger particles deposit in the oropharynx, while smaller ones are exhaled. Formulators must use micronization, spray drying, or jet milling to achieve the desired size.

2. Drug Solubility and Stability

Many respiratory APIs are poorly water-soluble. Formulators may use co-solvents, surfactants, or complexation techniques to maintain solubility and stability in liquid forms. For DPIs, carrier selection (e.g., lactose) and moisture control are essential.

3. Device-Formulation Compatibility

The formulation must not interact with device materials or valves. In MDIs, propellant compatibility is a critical parameter. For nasal sprays, viscosity and surface tension influence spray pattern and droplet size.

4. Nasal Mucociliary Clearance

Rapid clearance of nasal drugs due to mucociliary action can reduce efficacy. Mucoadhesive polymers such as chitosan, HPMC, or carbomers are used to prolong residence time.

5. Irritation and Safety

Inhaled or intranasal drugs must not irritate the mucosa. Hypertonic solutions, preservatives (like benzalkonium chloride), or surfactants can trigger local reactions or inflammation if not properly evaluated.

6. Dosing Accuracy and Patient Use

Dose delivery must be reproducible and device operation should be intuitive. For DPIs, inspiratory flow rate affects dose emitted. Devices must be designed considering pediatric, geriatric, and acute-use populations.

Regulatory Considerations

Inhalation and nasal products are subject to stringent regulation due to their complex nature and risk of local tissue damage or inconsistent dosing. Agencies such as USFDA, EMA, and WHO have specific guidelines for these delivery systems.

Key regulatory expectations include:

• Device-Drug Combination Approval: The device and drug are reviewed as a single unit. Device usability, labeling, and human factors studies are required.
• In Vitro Characterization: For inhalers, testing includes cascade impaction (e.g., Andersen or NGI), emitted dose, fine particle fraction, spray pattern, and plume geometry.
• Nasal Deposition Studies: IVRT (In Vitro Release Testing) and IVPT (In Vitro Permeation Testing) are used to assess drug delivery and mucosal retention.
• Microbial Limits and Preservative Efficacy: Especially important for multi-dose nasal sprays. Testing as per GMP guidance and pharmacopeias is required.
• Stability Studies: As per ICH guidelines, must evaluate drug content, device functionality, microbiology, and aerodynamic performance over shelf life.
• Bioequivalence: For generic inhalers or nasal sprays, clinical endpoint studies, pharmacokinetics, and in vitro comparability may be required.

Documentation must include SOPs for manufacturing, assembly, cleaning, and visual inspection of device components and filled units.

Best Practices in Formulation and Manufacturing

To ensure safe, effective, and compliant products, the following practices are recommended for inhalation and nasal dosage forms:

1. Conduct Preformulation Studies: Characterize the drug’s solubility, hygroscopicity, and particle morphology. Use DSC and XRPD to assess polymorphism.
2. Select Suitable Device: Work closely with device partners to select MDIs, DPIs, or spray pumps compatible with the formulation and intended patient population.
3. Control Particle Engineering: Use controlled milling, spray drying, or supercritical fluid processing to achieve optimal size and dispersibility.
4. Validate Inhalation Testing Equipment: Ensure calibration of impactors, flow controllers, and actuation systems for reproducible aerosol testing.
5. Use Inert Packaging: Choose materials that prevent moisture ingress and are non-reactive with drug or propellants. Blister packs for DPIs and aluminum cans for MDIs are common.
6. Establish Environmental Controls: Maintain low humidity (<30%) for DPI manufacturing and proper HVAC controls to prevent contamination.
7. Train Personnel: Operators must be trained in device handling, filling, leak detection, and sampling procedures to avoid dosing errors.

Manufacturing areas for inhalation products require specialized containment systems, HEPA filtration, and strict particulate control as per regulatory standards.

Case Study: DPI Development for Anti-Asthmatic Drug

A pharmaceutical company sought to develop a DPI formulation of salmeterol xinafoate and fluticasone propionate. The goal was to create a lactose-based carrier system with consistent fine particle fraction and good flow properties.

Challenges and Solutions:

• Micronized APIs adhered excessively to carrier surface. Solution: Reduced surface energy by lactose coating with Mg-stearate.
• Flow issues in filling machine. Solution: Optimized blend ratio, used vibration-assisted feeders, and included silica as a glidant.
• Low respirable fraction (<25%). Solution: Adjusted carrier particle size and added fines to improve deagglomeration.

The final product met USP and EMA specifications and passed bioequivalence studies. Post-launch, a patient training program was introduced to improve correct DPI usage and outcomes.

Conclusion

Inhalation and nasal dosage forms represent advanced and patient-centric solutions for fast and targeted drug delivery. Their success depends on harmonizing formulation science, device engineering, patient usability, and regulatory compliance.

As pulmonary and nasal vaccines, peptide delivery, and CNS-targeting therapies grow, the pharmaceutical industry must innovate and optimize these systems for precision, stability, and therapeutic impact.

Explore more about clinical evaluation of respiratory therapies at Clinical Studies, or enhance your knowledge of process and device validation at Pharma Validation.